• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Halozyme Therapeutics Inc

+ Add to Watchlist


9.5000 USD 0.0400 0.42%

As of 20:10:00 ET on 08/29/2014.

Snapshot for Halozyme Therapeutics Inc (HALO)

Open: 9.4900 Day's Range: 9.4200 - 9.6200 Volume: 579,291
Previous Close: 9.4600 52wk Range: 6.8800 - 18.1800 1-Yr Rtn: +14.32%

Stock Chart for HALO

No chart data available.
  • HALO:US 9.5000
  • 1D
  • 1M
  • 1Y
Interactive HALO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for HALO

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.7100
Est. EPS (USD) (12/2014) -0.6370
Est. PEG Ratio -
Market Cap (M USD) 1,190.40
Shares Outstanding (M) 125.31
30 Day Average Volume 1,175,083
Price/Book (mrq) 21.5247
Price/Sale (ttm) 18.9509
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/07/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for HALO

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.

Helen TorleyPresident/CEODavid A RamsayChief Financial Officer
H Michael Shepard "Mike"VP/Chief Scientific OfficerJean I LiuVP/Secretary/General Counsel
More Company Profile & Key Executives for HALO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil